The success story of biopharmaceuticals begins in 1982 and has continued since then. Every year, new biologics receive approval for the German market, thereby increasing the share of sales of all drugs - most recently to almost 18 percent. The growth is primarily due to the active ingredient group TNF-alpha inhibitors, which are used to treat inflammatory diseases such as rheumatoid arthritis, Crohn's disease or psoriasis. This study, carried out by INSIGHT Health, is intended to provide a brief overview of the development of biopharmaceuticals in the context of outpatient statutory health care. On the other hand, the second section focuses on the TNF-alpha inhibitors, which are by far the two highest-selling products in Germany.

Read more